MAIA Biotechnology, Inc. Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) - USD ($)	3 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023
Follow-on Offering
Issuance of common shares in connection with offering, issuance cost			$ 1,593,016
At-the-Market Equity Offering
Issuance of common shares in connection with offering, issuance cost	$ 315,314	$ 179,628
Private Placement Offering 1
Issuance of common shares in connection with offering, issuance cost		50,000
Private Placement Offering 2
Issuance of common shares in connection with offering, issuance cost		$ 47,261
Private Placement Offering 3
Issuance of common shares in connection with offering, issuance cost	$ 5,030